

Yacoub Yousef¹¹, Natia Esiashvili¹², Michael Sullivan¹³, Marcos Devanir da Costa¹⁴, Patricia Dastoli¹⁴, Fatima Mubarak¹⁵, Ute Bartels¹⁶, Omar Chandine¹⁷, Alan Davidson¹⁸, Awni Musharbash¹⁹, Patricia Alcasabas²⁰, Eric Bouffet¹⁶, and Simon Bailey²¹; ¹Pediatric Oncology Department, King Hussein Cancer Center, Amman, Jordan, ²Division of Endocrinology, Department of Pediatric Medicine, Faculty of Health Sciences, UCT, Cape Town, South Africa, ³Radiation Oncology Department, National Cancer Institute, Cairo University & Children's Cancer Hospital, Cairo, Egypt, ⁴Department of Neurosurgery, Red Cross War Memorial Children's Hospital and University of Cape Town, Cape Town, South Africa, ⁵Division of Neurosurgery, Pediatric Oncology Institute/GRAACC, Universidade Federal de São Paulo, São Paulo, Brazil, ⁶Department of Pediatrics and Pediatric Hematology/Oncology, University Children's Hospital, Klinikum Oldenburg AöR, Oldenburg, Germany, ⁷Clinical Oncology department, National Cancer Institute, University of Gezira, Gezira State, Sudan, ⁸Department of Radiation Oncology, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa, ⁹Department of Pediatric Hematology and Oncology, Aga Khan University Hospital, Karachi, Pakistan, ¹⁰Department of Neurosurgery, Kasr Al-Ainy School of Medicine, Children's Cancer Hospital Egypt, Cairo, Egypt, ¹¹Ophthalmology division/ Surgery department, King Hussein Cancer Center, Amman, Jordan, ¹²Radiation Oncology Department, Winship Cancer Institute, Emory University, Atlanta, GA, USA, ¹³Department of Pediatric Hematology and Oncology, Royal Hospital for Sick Children, Melbourne, Australia, ¹⁴Division of Neurosurgery, Pediatric Oncology Institute/GRAACC, Universidade Federal de São Paulo, Sao Paulo, Brazil, ¹⁵Radiology Department, Aga Khan University, Karachi, Pakistan, ¹⁶Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada, ¹⁷Department of Pediatric Hematology Oncology and stem cell transplantation, King Fahad Specialist Hospital, Dammam, Saudi Arabia, ¹⁸Hematology-Oncology Service, Red Cross Children's Hospital, Department of Pediatrics and Child Health, University of Cape Town, Cape town, South Africa, ¹⁹Neurosurgery division/Surgery department, King Hussein Cancer Center, Amman, Jordan, ²⁰University of the Philippines-Philippine General Hospital, Manila, Philippines, ²¹Department of Pediatric Oncology, Great North Children's Hospital, Newcastle, United Kingdom

Pediatric craniopharyngioma is a rare tumor with excellent survival but significant long-term morbidities due to the loco-regional tumor growth or secondary to its treatment. Visual impairment, panhypopituitarism, hypothalamic damage and behavioral changes are amongst the main challenges. This tumor should be managed under the care of a multidisciplinary team to determine the optimum treatment within the available resources. This is particularly important for low middle-income countries (LMICs) where resources are variable. We provide a risk-stratified management guideline for children diagnosed with craniopharyngioma in a resource limited setting based on the service levels describing the facilities and personnel required for management as previously specified by the Pediatric Oncology in Developing Countries (PODC) committee of The International Society of Pediatric Oncology (SIOP). A multi-disciplinary group of neurosurgeons, radiation and pediatric oncologists, radiologists, pediatric endocrinologists and an ophthalmologist with experience in managing children with craniopharyngioma in LMIC setting was formed and carried online meetings to form a consensus guideline. The clinical characteristics (including the visual and endocrine presentations), suggestive radiological features as well as potential treatment options including surgery, radiotherapy and intra-cystic therapies were discussed in depth and in relation to available resources. In addition, hormonal management, pre- and post-operative PICU care and expected future complications related to craniopharyngioma and to follow up these children were discussed and documented in the guideline. We believe this guideline is a useful reference for health care providers in LMIC.

LINC-11. NEUROPATHOLOGY REVIEW OF LATIN AMERICAN CHILDHOOD AND ADOLESCENT BRAIN TUMOR PATIENTS: A MULTI-NATIONAL, MULTI-DISCIPLINARY PEDIATRIC NEURO-ONCOLOGY TELECONFERENCE EXPERIENCE

Diana S. Osorio¹, Christopher R. Pierson², Alvaro Lassaletta³, Andres Morales la Madrid⁴, Ibrahim Qaddoumi⁵, Ute Bartels⁶, Daniel R. Boue², and Jonathan L. Finlay¹; ¹The Division of Hematology, Oncology, Blood and Marrow Transplant, Nationwide Children's Hospital and the Ohio State University, Columbus, OH, USA, ²Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital and The Ohio State University, Columbus, OH, USA, ³Hospital Infantil Universitario Niño Jesús, Madrid, Spain, ⁴Pediatric Hematology/Oncology, Hospital St Joan de Déu, Barcelona, Spain, ⁵Global Pediatric Medicine, Oncology Department, St. Jude Children's Research Hospital, Memphis, TN, USA, ⁶Brain Tumour Program, Division of Hematology/Oncology Hospital for Sick Children, Toronto, ON, Canada

BACKGROUND: Pediatric brain tumor classification has undergone significant evolution over the last decade requiring a high-level of expertise and diagnostic techniques. Such advances have created challenges for patholo-

gists particularly in low-to-middle income countries (LMIC). We conduct weekly pediatric neuro-oncology teleconferences linking global pediatric neuro-oncologists from high-income countries (HIC) to review patients with pediatric subspecialists from Latin America. **METHODS:** Three to five patients are discussed weekly and second neuropathology review is offered when a high-level of suspicion emerges of a questionable diagnosis based on clinical and radiographical information. Nationwide Children's Hospital (NCH) provides second neuropathology review at no cost to institutions in Latin America that fulfill these criteria. **RESULTS:** From July 2015 to December 2019 NCH reviewed 54 pathology samples from eleven Latin American countries. Of these, 33 (61.1%) cases resulted in diagnostic changes, of which 28 (51.8%) were significant, impacting treatment plans and overall patient outcomes. The remaining 21 (38.9%) confirmed institutional diagnosis; however, in eight of these 21 cases additional molecular information and/or further tumor subtyping unavailable in their home country at the time (eg: BRAF, RELN-fusion, medulloblastoma subtyping) was provided. **CONCLUSIONS:** This study highlights the importance of centralized pathology review by institutions with the proper equipment, infrastructure and expertise in pediatric neuropathology. Furthermore, this documents the beneficial impact of teleconferencing for subspecialists in LMIC who must treat a wide variety of pediatric cancers with few resources and support. Additionally, our findings underscore the need for pediatric subspecialty training in LMIC.

LINC-12. COMBINED ADULT AND PAEDIATRIC NEURO-ONCOLOGY LONG-TERM SURVIVOR CLINIC EXPERIENCE FROM A TERTIARY CANCER CENTRE IN A LOW-MIDDLE-INCOME COUNTRY

Rahul Krishnatry^{1,2}, Maya Prasad^{1,2}, Girish Chinnaswamy^{1,2}, Abhishek Chatterjee^{1,2}, Jayant Goda^{1,2}, Epari Sridhar^{1,2}, Aliasgar Moiyadi^{1,2}, Prakash Shetty^{1,2}, Arushi Saha^{1,2}, Vikas Singh^{1,2}, Nayana Golambade^{1,2}, and Tejpal Gupta^{1,2}; ¹Tata Memorial Center, Mumbai, Maharashtra, India, ²HBNI University, Mumbai, Maharashtra, India

NeuroOncology survivor clinics (NOS) is uncommon in low-middle-income countries. We started combined (paediatric and adult) NOS clinic in our tertiary a cancer centre (Jan-2017) and review here the demographic, clinical-pathological and treatment spectrum for our paediatric (0-18years) and adult (>18years) survivors (>5years since their initial diagnosis) till date. Of total 312 patients registered, 198 (63.5%) were adults while 114 (36.5%) were paediatric at-diagnosis with median age (IQR) at presentation: 34 (23-41) and 9(6 - 13) years respectively. In both groups, only 33% were females. The median (IQR) time since diagnosis was 9 (9-14) and 8 (6-12) years respectively with 60% of paediatric turning into adult survivors. The commonest paediatric tumours were glioma (52, 45.6%), embryonal (34, 29.8%), and ependymoma (12, 10.5%) versus gliomas (114, 57.6%) and benign tumours (42, 21.2%) in adults. The low-grade-glioma comprised 90.4% of all pediatric gliomas and intermediate-grade (90%) in adults. The primary treatment consisted of radiotherapy and chemotherapy in 95% and 43% versus 99% and 36% in adults versus paediatric patients respectively. Temozolomide and multi-drug combinations were the commonest chemotherapy used in adults and paediatrics respectively. Relapse and retreatments were seen in 16.6 and 14% of adults and paediatric patients. There were two deaths each in each group since registration (median 12 months). Although the baseline diagnosis/treatment characteristics are different, survivors of both group had a similar number of retreatments and deaths. Combined survivor clinics may present an interesting and unique opportunity to learn and provide challenging service in this part of the world.

LINC-13. THE STATE OF PEDIATRIC NEURO-ONCOLOGY IN ARMENIA

Samvel Bardakhchyan^{1,2}, Armen Tananyan², Samvel Danielyan¹, Jemma Arakelyan^{1,2}, Sergio Mkhitarian³, Karen Bedirian⁴, Liana Safaryan¹, Mikayel Arustamyan⁵, and Gevorg Tamamyan^{1,2}; ¹Haematology Center after Prof. Yeolyan, Yerevan, Armenia, ²Yerevan State Medical University, Yerevan, Armenia, ³Berd Military Hospital, Berd, Armenia, ⁴City of Smile Charitable Foundation, Yerevan, Armenia, ⁵Ira Medical Group, Yerevan, Armenia

BACKGROUND: Every year in Armenia we have approximately 80-90 new pediatric cancer cases from which 10-15 are brain tumors (PBT). Here we try to summarize the current state of pediatric neuro-oncology in Armenia. **DISCUSSION:** In Armenia pediatric neuro-oncology is still in its first steps. Surgical treatment of PBTs is performed only in one medical center - "Sourb Astvatsamayr" Medical Center, with 7 practicing pediatric neurosurgeons. Radiation therapy service with two linear accelerators is located at the "National Oncology Center", however there are no dedicated pediatric radiation neuro-oncologists, and 2 specialists are treating pediatric tumors. Chemotherapy for all pediatric cancers currently is performed at the Pediatric Cancer and Blood Disorders Center of Armenia, established in